Clinical Study

Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study

Table 2

Patient characteristics.

(100%)

Gender, N (%)

Female68 (58.6%)
Histology, N (%)
Soft tissue sarcoma96 (82.8%)
 Leiomyosarcoma38 (32.8%)
 Liposarcoma23 (19.8%)
 Synovial sarcoma14 (12.1%)
 Undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma21 (18.1%)
Bone sarcoma20 (17.2%)
 Osteosarcoma8 (6.9%)
 Ewing’s sarcoma12 (10.3%)
Site, N (%)
 Extremity41 (35.3%)
 Retroperitoneum19 (16.4%)
 Superficial trunk and chest wall5 (4.3%)
 Head and neck2 (1.7%)
 Cutaneous1 (0.9%)
 Visceral non-GI12 (10.3%)
 Visceral GI2 (1.7%)
 Knee1 (0.9%)
 Hip0
 Shoulder1 (0.9%)
 Pelvis4 (3.5%)
 Femur/humerus2 (1.8%)
 Ribs0
 Other24 (20.7%)
 Missing2 (1.7%)
Site of metastases, N (%)
 CNS1 (0.6%)
 Lung74 (44.6%)
 Liver24 (14.5%)
 Soft tissue11 (6.6%)
 Locoregional28 (16.9%)
 Other25 (15.1%)
 Missing3 (1.8%)
Receiving chemotherapy, N (%)
Yes73 (62.9%)
Number of sites of metastases
 Mean (SD)1.4 (0.7)
 Minimum, maximum1, 3
Age at sarcoma diagnosis
 Mean (SD)47.7 (17.2)
 Minimum, maximum13.6, 83.7
Age at metastatic disease diagnosis
 Mean (SD)49.5 (17.1)
 Minimum, maximum16.1, 83.8
Age at attainment of current response status
 Mean (SD)51.6 (17)
 Minimum, maximum18.5, 84.3